Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Reaffirmed by HC Wainwright
MarketBeatHC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Wednesday.
HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Wednesday.